PER® Winter Lung Cancer Conference | Conference

Emerging TKIs Shake Up the Treatment Landscape for EGFR Exon 20 Insertion+ NSCLC

February 8th 2022

Lyudmila Bazhenova, MD, explores key challenges faced with diagnosing and appropriately treating patients with non–small cell lung cancer that harbors EGFR exon 20 insertion mutations and provides insight into the second-line options that have recently garnered regulatory approval.

Neoadjuvant Immunotherapy Proving to Be Effective, Safe Option in Lung Cancer

February 8th 2022

Checkpoint inhibitors are often used in the advanced stage, but Erin A. Gillaspie, MD, MPH, argues that the data show physicians should consider utilizing this class of agents earlier in treatment.

Dr. Hales on the Role of Multidisciplinary Care in Locally Advanced Lung Cancer

February 7th 2022

Russell Kenneth Hales, MD, discusses the role of multidisciplinary care in locally advanced lung cancer.

Dr. Levy on Potential Methods to Optimize Molecular Testing in Lung Cancer

February 7th 2022

Benjamin Philip Levy, MD, discusses potential methods to optimize molecular testing in lung cancer.

ADCs Showcase Impressive Activity, Second-Line Combos Seek to Raise the Bar in Quest to Target HER2+ NSCLC

February 7th 2022

Antibody-drug conjugates appear to have the most activity in those with non–small cell lung cancer and HER2 expression.

Repeat Molecular Testing Is Beneficial in EGFR+ NSCLC With Acquired Resistance

February 7th 2022

Repeat histologic evaluation and molecular testing in patients with EGFR-mutant non–small cell lung cancer who develop acquired resistance to osimertinib can deliver pertinent information that can help guide subsequent treatment decisions.

Abundance of Immunotherapy Combinations Leaves Treatment Selection Unclear in Advanced NSCLC

February 7th 2022

Although PD-L1 expression and histology served as helpful stratification factors in pivotal trials, the paradigm will need to build out more tailored selection strategies as additional checkpoint inhibitors move through development.

Investigators Set Sights Beyond the PACIFIC Regimen in Unresectable Stage III NSCLC

February 7th 2022

Concurrent chemoradiation followed by durvalumab has become the standard of care for patients with unresectable stage III non–small cell lung cancer based on the results of the phase 3 PACIFIC trial. However, several strategies are under clinical evaluation to push the paradigm beyond the PACIFIC regimen.

Immunotherapy Advances Drive Progress in Lung Cancer Treatment

February 5th 2022

In the past 2 years, key data from clinical trials in advanced lung cancer have demonstrated that immunotherapy has expanded the bounds of the armamentarium for the treatment of several lung cancers.

Dr. Basu Roy on Addressing Barriers to Biomarker Testing in Lung Cancer

February 5th 2022

Upal Basu Roy, PhD, MPH, discusses addressing barriers to biomarker testing in lung cancer.

Dr. Hales on Investigational Treatment Strategies to Build Upon the PACIFIC Trial Results in Stage III NSCLC

February 5th 2022

Russell Kenneth Hales, MD, discusses investigational treatment strategies that have the potential to build upon the positive results of the phase 3 PACIFIC trial in stage III non–small cell lung cancer.

Neoadjuvant, Adjuvant Immunotherapies Poised to Revolutionize Outcomes in Resectable NSCLC

February 5th 2022

Surgical resection remains the key treatment modality for early-stage non–small cell lung cancer; however, both systemic adjuvant and neoadjuvant therapeutics are options that have value for patients.

RNA-Based NGS Offers the Potential to Identify More Patients With Rare Alterations in NSCLC

February 4th 2022

The field of non–small cell lung cancer has exploded with continuous advances in targeted therapies directed toward key molecular alterations, including rare mutations like MET exon 14 skipping mutations, RET rearrangements, and ROS1 mutations.

Borghaei Breaks Down Choices in Immunotherapy Approaches in Lung Cancer

February 8th 2021

With the emergence of multiple immunotherapy approaches in recent years, the decision of whether to use a single agent, to pair it with chemotherapy, or to pair it with another immunotherapy agent has come to the forefront of treatment.

Dr. Brahmer on Determining When to Start Immunotherapy in Frontline NSCLC

February 8th 2021

Julie R. Brahmer, MD, discusses factors to consider when determining when to initiate immunotherapy in a patient with newly diagnosed non–small cell lung cancer.

Dr. Raez on the Potential Utility of Cemiplimab in NSCLC

February 8th 2021

Luis E. Raez, MD, discusses the potential utility of cemiplimab-rwlc in non–small cell lung cancer.

Strategizing Effective Ways to Overcome TKI Resistance in ALK+ NSCLC

February 8th 2021

Vincent Lam, MD, describes frontline indications for this patient population, as well as strategies that can be utilized to overcome TKI resistance in later lines of therapy.

Forde Recaps Chemoimmunotherapy Activity in PD-L1–Negative NSCLC

February 8th 2021

Immunotherapy plus chemotherapy is a standard of care for patients with advanced PD-L1–negative non–small cell lung cancer who do not harbor actionable driver mutations.

New Options Spark Sequencing and Biomarker Trials in Mesothelioma

February 7th 2021

Now that a new standard of care has been established in frontline mesothelioma, clinical trials are needed to evaluate optimal sequencing with checkpoint inhibitors in the salvage setting and determine whether biomarkers of response to immunotherapy could further tailor treatment to individual patients.

Future of Frontline EGFR+ NSCLC Features TKI, Chemo Combos and Improved Molecular Profiling

February 7th 2021

Synergizing EGFR TKIs with antiangiogenic agents and chemotherapy, as well as improving the use of molecular classification, are novel strategies aimed at taking the frontline setting for patients with EGFR-mutant non–small cell lung cancer to the next level.